Ascentage Pharma Group International - American Depository Shares

Founder‑led with deep scientific credentials and global development experience. Governance is cleaner than many China issuers, with a Cayman parent and no VIE structure. A concert‑party arrangement among co‑founders and affiliates controls a meaningful stake, aligning incentives but concentrating influence.

Execution across China approvals, NRDL negotiation, and multi‑country Phase 3 trial operations has been solid. The next test is U.S./EU regulatory engagement and commercial partnering.